{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:29:40Z","timestamp":1772234980572,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"DOI":"10.1093\/jac\/dkm063","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T06:23:51Z","timestamp":1173767031000},"page":"1025-1030","source":"Crossref","is-referenced-by-count":22,"title":["Activity of faropenem against cephalosporin-resistant Enterobacteriaceae"],"prefix":"10.1093","volume":"59","author":[{"given":"Shazad","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,3,12]]},"reference":[{"key":"key\n\t\t\t\t20171010152124_DKM063C1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkl217","article-title":"Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England","volume":"58","author":"Potz","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dkl505","article-title":"A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum \u03b2-lactamases","volume":"59","author":"Ensor","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jac\/dki124","article-title":"BSAC standardized disc susceptibility testing method (version 4)","volume":"56","author":"Andrews","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jac\/dkf098","article-title":"In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe","volume":"50","author":"Milatovic","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jac\/dkl309","article-title":"Molecular characterization of plasmids encoding CTX-M-15 \u03b2-lactamases from Escherichia coli strains in the United Kingdom","volume":"58","author":"Karisik","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010152124_DKM063C8","first-page":"16","article-title":"Influence of food intake on the pharmacokinetics, safety and tolerability of a single dose of faropenem daloxate","author":"Voith"},{"key":"key\n\t\t\t\t20171010152124_DKM063C9","first-page":"411","article-title":"Prospective randomized double-blind study comparing faropenem daloxate 300 mg p.o. bid for 5 days with trimethoprim\/sulfamethoxazole (TMP\/SMX) 160\/800 mg p.o. bid for 5 days in treatment of patients with acute, uncomplicated lower urinary tract infections (uUTI). Study 100286","author":"Richard"},{"key":"key\n\t\t\t\t20171010152124_DKM063C10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.11150\/kansenshogakuzasshi1970.76.928","article-title":"Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and\/or benign prostatic hypertrophy","volume":"76","author":"Muratani","year":"2002","journal-title":"Kansenshogaku Zasshi"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/59\/5\/1025\/2173921\/dkm063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T22:12:23Z","timestamp":1507673543000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/59\/5\/1025\/729977\/Activity-of-faropenem-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,12]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,3,12]]},"published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm063","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,5]]},"published":{"date-parts":[[2007,3,12]]}}}